U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C49H54F2N8O6
Molecular Weight 889.0017
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LEDIPASVIR

SMILES

CC(C)[C@@]([H])(C(=O)N1CC2(CC2)C[C@@]1([H])c3ncc(-c4ccc5-c6ccc(cc6C(c5c4)(F)F)-c7ccc8c(c7)[nH]c([C@]9([H])[C@@]%10([H])CC[C@]([H])(C%10)N9C(=O)[C@]([H])(C(C)C)N=C(O)OC)n8)[nH]3)N=C(O)OC

InChI

InChIKey=VRTWBAAJJOHBQU-KMWAZVGDSA-N
InChI=1S/C49H54F2N8O6/c1-24(2)39(56-46(62)64-5)44(60)58-23-48(15-16-48)21-38(58)42-52-22-37(55-42)28-9-13-32-31-12-8-26(18-33(31)49(50,51)34(32)19-28)27-10-14-35-36(20-27)54-43(53-35)41-29-7-11-30(17-29)59(41)45(61)40(25(3)4)57-47(63)65-6/h8-10,12-14,18-20,22,24-25,29-30,38-41H,7,11,15-17,21,23H2,1-6H3,(H,52,55)(H,53,54)(H,56,62)(H,57,63)/t29-,30+,38-,39-,40-,41-/m0/s1

HIDE SMILES / InChI

Molecular Formula C49H54F2N8O6
Molecular Weight 889.0017
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/?term=23384816; http://www.ncbi.nlm.nih.gov/pubmed/?term=22314425

Ledipasvir is an inhibitor of the Hepatitis C Virus (HCV) NS5A protein required for viral RNA replication and assembly of HCV virions. Approved in October 2014 by the FDA, ledipasvir and sofosbuvir (tradename Harvoni) are direct-acting antiviral agents indicated for the treatment of HCV genotype 1 with or without cirrhosis.

CNS Activity

Curator's Comment:: Low levels of C14-ledipasvir-derived radioactivity were observed in the CNS

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
141 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
HARVONI

Approved Use

Indicated for the treatment of patients with chronic hepatitis C virus (HCV) genotype 1, 4, 5, or 6 infection

Launch Date

1412899200000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
323 ng/mL
90 mg 1 times / day steady-state, oral
dose: 90 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: [NO STEREO] PSI-7851|[NO STEREO] SOFOSBUVIR
[NO STEREO] LEDIPASVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
531 ng/mL
45 mg 1 times / day multiple, oral
dose: 45 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: [NO STEREO] PSI-7851|[NO STEREO] SOFOSBUVIR
[NO STEREO] LEDIPASVIR plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
7290 ng × h/mL
90 mg 1 times / day steady-state, oral
dose: 90 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: [NO STEREO] PSI-7851|[NO STEREO] SOFOSBUVIR
[NO STEREO] LEDIPASVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
9320 ng × h/mL
45 mg 1 times / day multiple, oral
dose: 45 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: [NO STEREO] PSI-7851|[NO STEREO] SOFOSBUVIR
[NO STEREO] LEDIPASVIR plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
47 h
90 mg 1 times / day steady-state, oral
dose: 90 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: [NO STEREO] PSI-7851|[NO STEREO] SOFOSBUVIR
[NO STEREO] LEDIPASVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
0.2%
90 mg 1 times / day steady-state, oral
dose: 90 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: [NO STEREO] PSI-7851|[NO STEREO] SOFOSBUVIR
[NO STEREO] LEDIPASVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
90 mg 1 times / day multiple, oral
Highest studied dose
Dose: 90 mg, 1 times / day
Route: oral
Route: multiple
Dose: 90 mg, 1 times / day
Sources:
unhealthy, 49 years
Health Status: unhealthy
Age Group: 49 years
Sex: M+F
Sources:
PubMed

PubMed

TitleDatePubMed
Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials.
2015 Jun
Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection.
2015 Mar 24-31
Interferon-free therapy for hepatitis C: The hurdles amid a golden era.
2015 Sep
Patents

Patents

Sample Use Guides

One tablet (90 mg of ledipasvir and 400 mg of sofosbuvir) taken orally once daily with or without food. Recommended treatment duration: treatment-naive with or without cirrhosis: 12 week. Treatment-experienced without cirrhosis: 12 weeks. Treatment-experienced with cirrhosis: 24 weeks. A dose recommendation cannot be made for patients with severe renal impairment or end stage renal disease.
Route of Administration: Oral
Ledipasvir inhibitory activity in vitro was characterized by EC50 of 0.031, 0.004, 10.8, 10.1 and 0.045 nM against GT1a, GT1b, GT2a, GT31 and GT4a, respectively.
Substance Class Chemical
Created
by admin
on Sat Jun 26 01:23:55 UTC 2021
Edited
by admin
on Sat Jun 26 01:23:55 UTC 2021
Record UNII
013TE6E4WV
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LEDIPASVIR
DASH   INN   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
HARVONI COMPONENT LEDIPASVIR
Brand Name English
LEDIPASVIR [VANDF]
Common Name English
LEDIPASVIR ACETONATE [JAN]
Common Name English
LEDIPASVIR [MI]
Common Name English
LEDIPASVIR [INN]
Common Name English
LEDIPASVIR COMPONENT OF HARVONI
Brand Name English
LEDIPASVIR [WHO-DD]
Common Name English
LEDIPASVIR [USAN]
Common Name English
GS-5885
Code English
LEDIPASVIR [ORANGE BOOK]
Common Name English
Classification Tree Code System Code
WHO-ATC J05AX65
Created by admin on Sat Jun 26 01:23:55 UTC 2021 , Edited by admin on Sat Jun 26 01:23:55 UTC 2021
NDF-RT N0000191256
Created by admin on Sat Jun 26 01:23:55 UTC 2021 , Edited by admin on Sat Jun 26 01:23:55 UTC 2021
FDA ORPHAN DRUG 535916
Created by admin on Sat Jun 26 01:23:55 UTC 2021 , Edited by admin on Sat Jun 26 01:23:55 UTC 2021
EMA ASSESSMENT REPORTS HARVONI (AUTHORIZED: HEPATITIS C, CHRONIC)
Created by admin on Sat Jun 26 01:23:55 UTC 2021 , Edited by admin on Sat Jun 26 01:23:55 UTC 2021
NCI_THESAURUS C281
Created by admin on Sat Jun 26 01:23:55 UTC 2021 , Edited by admin on Sat Jun 26 01:23:55 UTC 2021
WHO-ATC J05AP51
Created by admin on Sat Jun 26 01:23:55 UTC 2021 , Edited by admin on Sat Jun 26 01:23:55 UTC 2021
Code System Code Type Description
DRUG BANK
DB09027
Created by admin on Sat Jun 26 01:23:55 UTC 2021 , Edited by admin on Sat Jun 26 01:23:55 UTC 2021
PRIMARY
DRUG CENTRAL
4899
Created by admin on Sat Jun 26 01:23:55 UTC 2021 , Edited by admin on Sat Jun 26 01:23:55 UTC 2021
PRIMARY
NCI_THESAURUS
C129019
Created by admin on Sat Jun 26 01:23:55 UTC 2021 , Edited by admin on Sat Jun 26 01:23:55 UTC 2021
PRIMARY
LACTMED
Ledipasvir
Created by admin on Sat Jun 26 01:23:55 UTC 2021 , Edited by admin on Sat Jun 26 01:23:55 UTC 2021
PRIMARY
NDF-RT
N0000185503
Created by admin on Sat Jun 26 01:23:55 UTC 2021 , Edited by admin on Sat Jun 26 01:23:55 UTC 2021
PRIMARY P-Glycoprotein Inhibitors [MoA]
MERCK INDEX
M11788
Created by admin on Sat Jun 26 01:23:55 UTC 2021 , Edited by admin on Sat Jun 26 01:23:55 UTC 2021
PRIMARY
EPA CompTox
1256388-51-8
Created by admin on Sat Jun 26 01:23:55 UTC 2021 , Edited by admin on Sat Jun 26 01:23:55 UTC 2021
PRIMARY
INN
9796
Created by admin on Sat Jun 26 01:23:55 UTC 2021 , Edited by admin on Sat Jun 26 01:23:55 UTC 2021
PRIMARY
CAS
1256388-51-8
Created by admin on Sat Jun 26 01:23:55 UTC 2021 , Edited by admin on Sat Jun 26 01:23:55 UTC 2021
PRIMARY
FDA UNII
013TE6E4WV
Created by admin on Sat Jun 26 01:23:55 UTC 2021 , Edited by admin on Sat Jun 26 01:23:55 UTC 2021
PRIMARY
RXCUI
1591922
Created by admin on Sat Jun 26 01:23:55 UTC 2021 , Edited by admin on Sat Jun 26 01:23:55 UTC 2021
PRIMARY RxNorm
ChEMBL
CHEMBL2374220
Created by admin on Sat Jun 26 01:23:55 UTC 2021 , Edited by admin on Sat Jun 26 01:23:55 UTC 2021
PRIMARY
EVMPD
SUB120165
Created by admin on Sat Jun 26 01:23:55 UTC 2021 , Edited by admin on Sat Jun 26 01:23:55 UTC 2021
PRIMARY
PUBCHEM
67505836
Created by admin on Sat Jun 26 01:23:55 UTC 2021 , Edited by admin on Sat Jun 26 01:23:55 UTC 2021
PRIMARY
NDF-RT
N0000190113
Created by admin on Sat Jun 26 01:23:55 UTC 2021 , Edited by admin on Sat Jun 26 01:23:55 UTC 2021
PRIMARY Breast Cancer Resistance Protein Inhibitors [MoA]
WIKIPEDIA
Ledipasvir
Created by admin on Sat Jun 26 01:23:55 UTC 2021 , Edited by admin on Sat Jun 26 01:23:55 UTC 2021
PRIMARY
Related Record Type Details
TRANSPORTER -> SUBSTRATE
LDV is a substrate for P-gp and BCRP in vitro (AD-256-2144 and AD-256-2150).
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
TRANSPORTER -> SUBSTRATE
LDV is a substrate for P-gp and BCRP in vitro (AD-256-2144 and AD-256-2150).
BINDER->LIGAND
LDV is >99.8% bound to human plasma proteins when determined in vitro with equilibrium dialysis. In agreement with in vitro data, LDV protein binding was ? 98% in healthy subjects and in subjects with renal or hepatic impairment.
BINDING
EXCRETED UNCHANGED
Unchanged LDV was the major component excreted in feces and accounted for a mean of 70% of the administered dose, but no unchanged parent drug was detected in urine.
FECAL
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC ONCE-DAILY DOSING

Tmax PHARMACOKINETIC ORAL ADMINISTRATION